85 results about "Axon growth" patented technology

The present invention provides methods and compositions for enhancing regeneration and / or repair of neural tissue. One method include providing a nanoscale structured material at the site of injury, wherein the nanoscale structured material provides an environment that is permissive for regeneration of neural tissue and allows axon growth from a location on one side of a site of injury or barrier to a location on the other side of the site of injury or barrier. A second method includes introducing a composition comprising self-assembling peptides into the subject at the site of injury, wherein the peptides are amphiphilic peptides that comprise substantially equal proportions of hydrophobic and hydrophilic amino acids and are complementary and structurally compatible. A variety of compositions comprising a nanoscale structured material or precursor thereof, and an additional substance such as a regeneration promoting factor, are also provided. In certain embodiments of the invention the nanoscale structured material or precursor thereof comprises self-assembling peptides. The invention further provides compositions and methods for repair of an intervertebral disc, including nucleus pulpusos repair.

The Rho family GTPases regulates axon growth and regeneration. Inactivation of Rho with C3, a toxin from Clostridium botulinum, can stimulate regeneration and sprouting of injured axons. The present invention provides novel chimeric C3-like Rho antagonists. The invention further provides evidence that these compounds promote repair when applied to the injured mammalian central nervous system, such as the retina. The present invention provide agents which are able to diffuse readily and therefore can promote repair for neurodegenerative disease of the eye, such as macular degeneration. The present invention further provides methods of treating macular degeneration, methods of inhibiting or reducing the rate of subretinal neovascularization and proliferation of neovascular tissue and methods of protecting retinal photoreceptor cell death.

The present invention provides methods for making, delivering and using formulations that combine a therapeutically active agent(s) (such as for example a Rho antagonist(s)) and a flowable carrier component capable of forming a therapeutically acceptable matrix in vivo (such as for example tissue adhesives), to injured nerves to promote repair and regeneration and regrowth of injured (mammalian) neuronal cells, e.g. for facilitating axon growth at a desired lesion site. Preferred active agents are known Rho antagonists such as for example C3, chimeric C3 proteins, etc. or substances selected from among known trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane compounds or Rho kinase inhibitors. The system for example may deliver an antagonist(s) in a tissue adhesive such as, for example, a fibrin glue or a collagen gel to create a delivery matrix in situ. A kit and methods of stimulating neuronal regeneration are also included.

The invention relates to a conductive parallel fiber membrane which is capable of promoting rapid repair of peripheral nervous tissues and is connected to an extracellular matrix, wherein the thin film (the fiber membrane) can serve as a biofunctional nerve scaffold. The conductive parallel fiber membrane which is connected to the extracellular matrix and is of a core-shell structure is prepared by virtue of a three-step method, namely preparing parallel fibers through electrostatic spinning, covering conductive polypyrrole through electrochemical oxidation, and conducting human skin fibroblast culture and splitting cells by virtue of a triton x-100 / ammonia water mixed solution. According to the invention, the composite fiber membrane, by virtue of the parallel structure, can guide the growth of nerve fibers in a directional mode, by virtue of the extracellular matrix, adhesion of the nerve cells and axon thereof is improved, and by virtue of the conductive polymer (the conductive polypyrrole), the growth of the nerve axon is promoted through electric stimulation; and with a synergistic effect among the three means, the regeneration and repair of nerves are promoted. A preparation device adopted by the invention is simple and easy, simple to operate, wide in material source and low in cost; and the prepared nerve scaffold is good in biocompatibility and functionality, and the nerve scaffold is expected to be applied to clinical field in the future.

The invention relates to a biological material used to recover hurt brain. Wherein, it uses transparent hyaluronic acid as raw material, guided by carbodiimide hydrochlorate (EDC), to use adipic acid adipoyl (ADH) to cross, to obtain the hyaluronic acid gel, as the carrier of graft antibody; and uses antibody solidification technique to graft the antibodies of axon growth restrain factor MAG, OMgp and Nogo-A to the hyaluronic acid gel, to be the antibody transfer system carrying special antibody and sensitive to pH value. The invention can be used to seal the never axon regeneration restrain factor of myelin and accelerate the regeneration of hurt brain organism.

This invention relates to the 5-cis and 5-trans isomers of geranylgeranyl acetone, preferably such synthetic isomers, and pharmaceutical compositions containing such isomers. Other aspects of this invention relate to the use of geranylgeranyl acetone and its isomers in methods for inhibiting neural death, increasing neural activity, and increasing axon growth and cell viability. Geranylgeranyl acetone is a known anti-ulcer drug used commercially and in clinical situations. GGA has also been shown to exert cytoprotective effects on a variety of organs, such as the eye, brain, and heart.

A robotic microfluidic incubator system has a thin transparent sidewall and close proximity of the embryo / oocyte / cultured cells to the sidewall allow close approach of a side view microscope with adequate focal length for mid to high power. This arrangement permits microscopic examination of multiple culture wells when arranged in rows (linear or along the circumference of a carousel). Manual or automated side to side movement of the linear well row, or rotation of the carousel, allows rapid inspection of the contents each well. Automated systems with video capability also allow remote inspection of wells by video connection or Internet connection, and automated video systems can record oft-hours inspections or time lapse development in culture (i.e. embryo cell division progression, or axon growth in neuron cell cultures).

The invention provides PirB extracellular polypeptide which potentially treats central lesion. The polypeptide has an extracellular amino acid sequence of a paired immunoglobin-like receptor. The polypeptide segment can be massively expressed in escherichia coli and combined with myelin inhibiting factors MAG, Nogo-66 and OMgp in high affinity, so as to antagonize the bioactivity and function of PirB. The PEP provided by the invention can be effectively combined with myelin inhibiting factors MAG, Nogo-66 and OMgp so as to promote axon growth. The PEP provided by the invention can be massively prepared, is low in cost and high in activity, can be used for preparing medicines for treating various CNS (Central Nervous System) damages such as cerebral ischemia and anoxia, cerebral hemorrhage, cerebral trauma and spinal cord injury, and can effectively promote the regeneration of nervous tissues and neural functional recovery.

The invention belongs to the technical field of medicines and particularly relates to a pharmaceutical composition. The pharmaceutical composition contains fasudil hydrochloride and nucleotide derivatives, wherein the content of the nucleotide derivatives in the pharmaceutical composition is 0.1-25 times of the content of the fasudil hydrochloride. The invention also discloses a preparation method and application of the pharmaceutical composition. The pharmaceutical composition has the effects of improving the activity of myosin light chain phosphatase to expand blood vessels, reducing the tensions of endothelial cells, improving microcirculation of brain tissues, protecting nerve to avoid apoptosis and promoting nerve regeneration so as to prevent and reduce cerebral vasospasm caused by various reasons and selectively expand the spasmodic blood vessels; and the pharmaceutical composition can also be used for inhibiting the damage of cerebral neurons, promoting the axon growth of neural cells and relieving the inflammatory response of involved brain cells.

The invention relates to structures of five new ent-atisane diterpenoid compounds (1-5), a preparation method and application of the five new ent-atisane diterpenoid compounds (1-5) in anti-inflammatory and neurodegenerative disease treatment drugs. The new compounds (1-5) have the following structures as shown in the specification. The five new compounds provided by the invention have NO inhibition and nerve axon growth promotion activity, and can be used for development and application of anti-inflammatory and neurodegenerative disease treatment drugs.

Disclosed are methods of treating chronic nervous system diseases or injuries, e.g., chronic spinal cord injury, using Nogo receptor antagonists, including Nogo receptor-1 (NgR1) polypeptides, Nogo receptor-1 antibodies and antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, and polynucleotides. Also disclosed are methods of noninvasively monitoring axonal growth during and after treatment with an axonal growth promoting agent.

The invention discloses an application of non-coding RNA (miR-132-5P) to a peripheral nerve regeneration process. The non-coding RNA (miR-132-5P) can promote peripheral extension regeneration by inhibiting the expression of the miR-132-5P. Rat miR-132-5p is knocked down and overexpressed through a genetic engineering technology, and results show that after the miR-132-5p is inhibited, the axon growth speed of neurons is increased, the nerve repair time is shortened, and the nerve function recovery is remarkable.

Disclosed are methods of treating chronic nervous system diseases or injuries, e.g., chronic spinal cord injury, using Nogo receptor antagonists, including Nogo receptor-1 (NgR1) polypeptides, Nogo receptor-1 antibodies and antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof, and polynucleotides. Also disclosed are methods of noninvasively monitoring axonal growth during and after treatment with an axonal growth promoting agent.